Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chemring YTD order book hits £1.3bn following 'significant orders'

(Sharecast News) - Defence technology group Chemring said on Wednesday that its FY25 trading performance looked set to be in line with expectations, with its order book significantly stronger year-to-date. Chemring said its order book was £1.35bn as of 30 January, up from £991.0m at the same time a year ago, with Q1 order intake hitting £393.0m thanks to "significant orders" across both sectors.

The FTSE 250-listed group said FY25 revenues were expected to be 81% covered by Q1 revenues and its current order book.

"The current financial year continues to plan and our outlook remains in line with market expectations. Our order book is at a record level and order intake across both sectors benefitted from the receipt of several significant orders, demonstrating continued customer demand and confidence in Chemring's market-leading products and services," said chief executive Michael Ord. "The group is increasingly well positioned, with a strong and sustainable platform for future growth."

Chemring also announced that it will commence a share buy-back programme for up to £40.0m as it looks to reduce its share capital.

As of 0900 GMT, Chemring shares were up 3.75% at 387.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.